Daiichi Sankyo : Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer (200.1KB

Press Release Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer Parallel applications based on TROPION-Lung01 and TROPION-Breast01 phase 3 trial results demonstrating Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan significantly improved progression-free survival versus chemotherapy in two [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.